Astellas ranked in recognition of its commitment and support for working mothers

- Enzalutamide is the first androgen receptor-inhibitor to demonstrate a statistically significant improvement in metastasis-free survival (MFS) in this patient population in a randomized, controlled clinical trial

If approved, the combination therapy could potentially offer a new treatment option for patients whose overactive bladder symptoms are not adequately controlled on monotherapy

Winner will attend live taping of ABC's "Dancing with the Stars"

For the third consecutive year, the pharmaceutical company was named to the 2017 Great Place to Work® ranking among medium-sized multinational businesses across all industries in the country

Moyra Knight, Andrew Lewis and Karl Uhlendorf named to key roles

Astellas to Retain Certain Promising Antibody-Drug Conjugate R&D Programs of Agensys